News and Announcements
OncoSil Medical CEO Presentation & AGM October 2016
- Published October 18, 2016 3:29PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
18th October 2016, ASX Announcement
Achievements Delivered FY16
September 2015 – Submission of CE Mark application for OncoSil™
October 2015 – OncoSil™ CE Mark application granted Fast Track review status
December 2015 – Investigational Device Exemption submitted to the FDA for OncoPac-1 clinical study
January 2016 – Chris Roberts appointed Independent Non-Executive Director
February 2016 – $10 million private placement to Regal Funds Management
March – April 2016 – Q-Submissions meeting with FDA
-Responses to CE Mark and FDA questions
May 2016 – OncoSil Medical completes hiring of senior management for the Leadership Team
June 2016 – IDE Amendment submitted to the FDA for OncoPac-1 clinical study
To view the full Presentation, please click on the button below.